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Intra- or extrahepatic cholangiocarcinomas are the second most common primary liver malignancies behind
hepatocellular carcinoma. Whereas the incidence for intrahepatic cholangiocarcinoma is rising, the occurrence
of extrahepatic cholangiocarcinoma is trending downwards. The treatment of choice for intrahepatic
cholangiocarcinoma remains liver resection. However, a case of liver resection after selective internal radiation
therapy in order to treat a recurrent intrahepatic cholangiocarcinoma in a transplant liver is unknown in the
literature so far. Herein, we present a case of a patient undergoing liver transplantation for Wilson’s disease with an
accidental finding of an intrahepatic cholangiocarcinoma within the explanted liver. Due to a recurrent intrahepatic
cholangiocarcinoma after liver transplantation, a selective internal radiation therapy with yttrium-90 microspheres was
performed followed by right hemihepatectomy. Four years later, the patient is tumor-free and in a healthy condition.
Keywords: Liver transplantation, Liver resection, Intrahepatic cholangiocarcinoma, Selective internal radiation therapyBackground
Patients suffering from unresectable intrahepatic cholan-
giocarcinoma have an overall poor prognosis as demon-
strated by a median survival of about three months in
untreated patients [1]. In the present case, the patient de-
veloped a recurrent intrahepatic cholangiocarcinoma (ICC)
in a transplant liver that was initially classified as unresect-
able. Possible treatment modalities for unresectable ICC
are systemic chemotherapy, loco-regional therapies and
best supportive care [2]. In selected patients and special-
ized centers, a neoadjuvant chemotherapy followed by liver
transplantation is also feasible [3]. At present, systemic
chemotherapy may be seen as the treatment of choice for
unresectable ICC [4]. However, a standardized treatment
strategy for patients with unresectable ICC has not yet
been established. According to the recently updated and
published guidelines for the management of ICC, loco-
regional therapies can be considered as treatment options* Correspondence: otto.kollmar@med.uni-goettingen.de
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unless otherwise stated.in such instances [5]. Selective internal radiation therapy
(SIRT) represents a promising loco-regional therapeutic
modality for ICC although there are only few data on this
issue and no randomized controlled trials until now [6-11].
However, the patient was treated with SIRT and showed
good radiological response. In consequence, right hemihe-
patectomy was performed. Four years later, the patient is
tumor free and in a healthy condition with sufficient liver
function. The present case report describes the clinical
course of the patient in detail and reviews the literature on
the management of ICC with SIRT.Case presentation
A 55-year-old patient with liver cirrhosis due to Wilson’s
disease developed a tumor in segment VI of the liver.
Whereas ultrasound-guided biopsy was not effective to
achieve a definitive histological diagnosis, the tumor was
highly suggestive of a hepatocellular carcinoma (HCC)
on computed tomography (CT) and magnetic resonance
imaging (MRI). The alpha-fetoprotein serum level was
13.5 IU/ml. The labMELD was 14. The tumor diameter
was 18 mm. According to our department standards,
HCC was the suspected diagnosis. This was in line with
the diagnostic algorithm recently updated and publishedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Magnetic resonance imaging of the transplant liver
before selective internal radiation therapy (SIRT). The arrow
points to the ICC in segment VII of the transplant liver.
Figure 2 Magnetic resonance imaging of the transplant liver
after selective internal radiation therapy (SIRT). Note the
necrosis within the tumor center of the ICC as indicated by the long
arrow. The small arrows point to fibrotic liver alterations due to SIRT.
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sociation for the Study of Liver Diseases) [12].
At the time of the suspected diagnosis, the patients
Child-Pugh Score was B. Due to the limited liver func-
tion combined with a restricted general condition,
(ECOG (Eastern Cooperative Oncology Group) Perform-
ance Status: 1 to 2), we refrained from a surgical resec-
tion. Thus, in line with the BCLC (Barcelona Clinic
Liver Cancer classification), the patient was considered
for liver transplantation. Moreover, we decided to per-
form a transarterial chemoembolization (TACE) as a
bridging therapy for tumor control. Therefore, the pa-
tient underwent four cycles of doxorubicin-based TACE
resulting in a stable disease for one year. According to
the Milan criteria, the patient was subsequently listed
for liver transplantation (LTx).
Six months later, one and a half years after the initial
tumor diagnosis, the patient underwent orthotopic LTx
using a venovenous axillofemoral bypass. Initial im-
munosuppression consisted of cyclosporine, azathioprine
and steroids. The peri- and postoperative course was un-
eventful and the patient was discharged from the hos-
pital on the 15th postoperative day. The tumor in the
explanted liver measured 17 × 15 × 14 mm. Surprisingly,
the pathological result revealed an ICC (pT1, pN0, GII,
R0) instead of the assumed HCC. Two lymph nodes next
to the bile duct were free of malignancy. One month
after LTx, the patient was admitted to the clinic with a
complete fascial dehiscence requiring emergency surgi-
cal revision with direct suture. Immunosuppression was
converted to tacrolimus monotherapy.
Four years after LTx, the patient developed a recurrent
ICC in segment VII of the transplant liver in close vicinity
to the inferior vena cava (Figure 1). A CT scan revealed no
signs of extrahepatic metastases. Immunosuppression was
switched to rapamycin. Due to the close vicinity to the
vena cava, tumor resection was considered to pose a sig-
nificant risk for the patient, especially in a transplant liver.
The case was intensively discussed by our interdisciplinary
tumor board. We decided against tumor resection consid-
ering that the ICC was unresectable with respect to its lo-
cation. Thus, the patient was evaluated for selective
internal radiation therapy (SIRT) and underwent a single
application of yttrium-90 microspheres (TheraSphere®,
Nordion, Ottawa, Canada). On the follow-up MRI scan
the tumor showed good radiological response with near
total tumor necrosis although with a slight increase in size
(Figure 2). Again, the case was intensively discussed by
our interdisciplinary tumor board. Due to the promising
radiological response but a high risk for tumor cell sur-
vival, we offered the patient the possibility of undergoing
surgical resection.
Due to the tumor location, fibrosis and radiation-
associated alteration of the surrounding liver, a righthemihepatectomy was performed using a Cavitron Ultra-
sonic Surgical Aspirator (CUSA®, Valleylab, Boulder, CO,
USA) for parenchymal dissection. Two weeks before
liver resection, immunosuppression was switched back to
tacrolimus to facilitate wound healing. The tumor size mea-
sured 60 × 50 × 42 mm (Figure 3). The histopathological
Figure 3 Macroscopic appearance of the resected specimen.
Note the fibrotic alteration of the adjacent liver.
Figure 4 Magnetic resonance imaging of the liver transplant
after resection with no evidence of recurrent disease.
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adjacent to 40% of vital tumor cells.
The postoperative course was complicated due to bil-
iary fistula from the resection margin, fascial necrosis
and symptomatic ileus requiring surgical revision, in-
cluding the implantation of a Permacol™ biologic im-
plant (Covidien, Mansfield, MA, USA) for definitive
abdominal wall closure. Six weeks after the final surgical
intervention, the patient was discharged from the hos-
pital in a good general condition with clean wounds.
After complete wound healing, immunosuppression was
reverted to rapamycin. Two years after resection of the
ICC, the transplant liver showed sufficient graft function
without signs for tumor recurrence (Figure 4). On the
latest follow-up, four years after tumor resection, the pa-
tient remains disease-free and in a healthy condition.
This case report is of interest for hepato-biliary and
liver transplant surgeons, as it describes the first case of
SIRT prior to right hemihepatectomy to treat an ICC
within a transplant liver.
Intra- or extrahepatic cholangiocarcinomas are the
second most common primary liver malignancies behind
HCC [13]. They are relatively rare, although with a rising
incidence worldwide [14]. In detail, several international
studies have shown that the incidence of ICC is rising,
whereas the occurrence of extrahepatic cholangiocarci-
noma (ECC) is trending downwards [15]. In case of an
ICC, surgical resection remains the only therapy that of-
fers long-term survival or even cure [13]. However, due
to bilobular tumor involvement or concomitant liver dis-
ease, curative surgery is feasible in only a few patients[13]. In contrast to HCC, for which LTx or TACE are
validated treatment options, little evidence of effective
alternatives to liver resection exist in the literature for
ICCs [16]. TACE is not recommended for this type of
tumor as ICCs are mainly fibrotic as well as non-
hypervascular and, therefore, not the ideal target for this
treatment modality. However, in the present case the
tumor was primarily treated with four cycles of TACE
assuming a HCC within the cirrhotic liver. Due to a lim-
ited liver function we decided against tumor resection.
Although resection can be performed in patients with
advanced liver disease, mortality is probably higher and
patients might be better served by liver transplantation
or ablation [12]. However, we do not perform a radiofre-
quency ablation but TACE. This therapy form was chosen
for tumor control in terms of a bridging therapy until liver
transplantation. Of interest, the tumor remained stable for
one year.
Whereas LTx is well established for HCC [17] it is far
from being a well accepted indication for ICC or ECC.
Regarding ECC, there are, beside careful patient selec-
tion, well defined neoadjuvant protocols prior to LTx
which have led to encouraging results for this tumor en-
tity [18-23]. However, the role of LTx in the manage-
ment of ICC still remains controversial because of organ
shortage, disease recurrence and the risk of accelerating
tumor progression under immunosuppression after
transplantation [13]. Farges et al. even claim that there
are only two exceptions where LTx for ICC lead to good
results: first, LTx for very small ICCs that have been
mistaken for HCC (like in our case) or incidentally
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ond, ECC from second order biliary branches, which can
be viewed as ICC and treated by an aggressive neoadju-
vant regimen [16]. However, the key determinant identi-
fied for a promising outcome is a low tumor stage [24,25].
ICCs with lymph node metastasis, vascular or bile duct in-
vasion remain contraindications for LTx [25].
In the present case, the patient underwent LTx with an
ICC in segment VI that was mistakenly diagnosed as
HCC. Our patient developed recurrent disease four years
after LTx, which is considered to be a very long time
period of tumor free survival. The recurrent tumor was
initially considered to be unresectable. Systemic chemo-
therapy may be seen as the treatment of choice in such
instances with, however, palliative intent [4]. To date, a
treatment strategy for these patients has not been stan-
dardized. Beside systemic chemotherapy, loco-regional
therapies can be performed in patients suffering from
non-resectable disease [5]. At present there are no estab-
lished first-line loco-regional therapeutic options for pa-
tients with unresectable ICC [5].
SIRT, however, represents a promising treatment mo-
dality although there are only few data on it and no ran-
domized controlled trials [6-11].
SIRT is a radioembolization procedure which is con-
sidered to be an effective liver-directed therapy with a
favorable therapeutic ratio that offers meaningful bene-
fits for selected patients [26,27]. SIRT is able to improve
survival after intrahepatic recurrence of ICC [10]. Of
interest, the antitumor effect of SIRT is rather related to
radiation than to embolization [28]. Thereby, it provides
a low toxicity profile and is able to deliver extremely
high doses up to small target volumes while sparing the
surrounding liver tissue [29]. It remains debatable if the
clinical situation in the present case is comparable to a
recurrent ICC in a non-transplanted liver. However, after
discussing the case in our interdisciplinary tumor board
meetings, we decided to treat the patient with SIRT as-
suming that he was in an overall non-curative situation.
SIRT can be conducted to downsize the intrahepatic
tumor mass, because it is known that the use of yttrium-
90 microspheres is useful for this purpose and might
make the surgical resection easier [30]. In the present
case, SIRT led to relevant tumor necrosis as demon-
strated by good radiological response. Thus, we decided
to offer the patient surgical resection. However, due to
relevant fibrosis combined with radiation-associated al-
teration induced by SIRT, right hemihepatectomy was
needed while initially a limited resection may have been
possible. To the best of our knowledge no similar case
has been reported in the literature so far.
Another important issue in dealing with liver resection
in a transplant liver is immunosuppression. The mTOR
(mammalian target of rapamycin)-inhibitor rapamycin isknown to inhibit tumor growth in vitro and in vivo
[31-34]. Therefore, this drug provides the advantage
of combining immunosuppression with anticancer ther-
apy. The most important side effect of rapamycin is its
negative influence on wound healing caused by its anti-
angiogenetic component [35]. In the present case, the
rapamycin-induced-immunosuppression was switched back
to tacrolimus two weeks before liver resection to facilitate
wound healing.
Nevertheless, the patient developed a biliary fistula
combined with fascial necrosis. It may be that these
complications might have been preventable if the
mTOR-inhibitor had been stopped earlier. From our ex-
periences it could, therefore, be recommended for re-
peated surgery in LTx-patients under mTOR-inhibition,
that immunosuppression should be switched to tacroli-
mus or cyclosporine at least four weeks before surgery.
After complete wound healing, the immunosuppression
could then be reverted to mTOR-inhibition.
In addition, abdominal wall hernia is one of the most
common surgical problems after LTx with an incidence
ranging between 4.6 and 23% [36,37]. Hernia repair with
synthetic mesh graft showed good results, although
these grafts have a high risk of infection leading to post-
operative wound healing complications [38,39]. In the
present case, we successfully used a Permacol™ implant
for the infected hernia side classified grade 3 to 4 ac-
cording to the Ventral Hernia Working Group [40].Conclusion
In conclusion, we demonstrated for the first time a
multimodal treatment approach for ICC, including LTx
for the primary ICC and SIRT prior to liver resection for
recurrent/de novo ICC, with encouraging results. Fur-
thermore, we were able to show that an abdominal wall
hernia in an infected hernia site after LTx can be suc-
cessfully repaired with a Permacol® biologic implant.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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